patent_istock-643607264_warchi-
warchi / iStockphoto.com
14 June 2018PharmaEllen Sherin

Investing in patent search: tips for practitioners

What is the cost of a single missed reference in the IP world? It depends on the situation. Research programmes that spend millions to develop inventions which turn out to be unpatentable because of prior art, long drawn-out prosecutions with multiple rejections, post-grant invalidities and infringement litigation are just some of the possibilities. No search is perfect, and there is always the chance of missing something—but the better the search, the better the subsequent decision-making.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
31 July 2026   A director review has overturned a PTAB ruling, questioning why it diverged from an ITC decision based on the same patent claims, prior art and evidence.
Pharma
23 July 2026   Canada has firmly slammed the door on patenting methods of medical treatment—but the battle over what counts as a "medical method" is only just beginning. Scott MacKendrick of ROBIC examines a landmark decision that leaves the door ajar for future litigation over complex drug-dosing regimens.
Pharma
9 July 2026   Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.